Mechanisms of immune escape in vital hepatitis

Gut

Volumn 44, Issue 5, 1999, Pages 759-764

  Rosenberg, W ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGENICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS HEPATITIS;

EID: 0033005331     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.5.759     Document Type: Review

References (78)

1. 1 Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
2. 2 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995,13:29-60.
3. 3 Klenerman P, Hengartner H, Zinkernagel RM. A non-retroviral RNA virus persists in DNA form. Nature 1997;390:298-301.
4. 4 Weiss RA, Kellam P. Illicit viral DNA. Nature 1997;390:235-6.
5. 5 Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998;91:3841-9.
6. 6 Bonino F, Brunetto MR, Rizzetto M, et al. Hepatitis B virus unable to secrete e antigen. Gastroenterology 1991;100:1138-41.
7. 7 Carman WF, Thomas HC. Genetic variation in hepatitis B virus. Gastroenterology 1992;102:711-19.
8. 8 Kato J, Hasegawa K, Torii N, et al. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996;23:389-95.
9. 9 Protzer Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-63.
10. 10 Hiasa Y, Horiike N, Akbar SM, et al. Low stimulatory capacity of lymphoid dendritic cells expressing hepatitis C virus genes. Biochem Biophys Res Commun 1998;249:90-5.
11. 11 van Doorn LJ, Capriles I, Maertens G, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995;69:773-8.
12. 12 Watkins BA, Buge S, Aldrich K, et al. Resistance of human immunodeficiency virus type I to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol 1996;70:8431-7.
13. 13 Townsend A, Bodmer H. Antigen recognition by class 1-restricted T lymphocytes. Annu Rev Immumol 1989;7:601-24.
14. 14 Cresswell P. Assembly, transport, and function of MHC class II molecules. Ann Rev Immunol 1994;12;259-94.
15. 15 Rotem Yehudar R, Winograd S, Sela S, et al. Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12. J Exp Med 1994;180:477-88.
16. 16 de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
17. 17 Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-7.
18. 18 Phillips RF, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-9.
19. 19 Masucci MG, Zhang QJ, Gavioli R, et al. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. Int Immunol 1992;4:1283-92.
20. 20 Sette A, Alexander J, Ruppert J, et al. Antigen analogs/mhc complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994;12:413-31.
21. 21 Ostrov D, Krieger J, Sidney J, et al. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. J Immunol 1993;150:4277-83.
22. 22 Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature 1994;369: 403-7.
23. 23 Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369:407-10.
24. 24 Carman WF, Boner W, Fattovich G, et al. Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. J Infect Dis 1997;175:1093-100.
25. 25 Weiner A, Erickson AL, Kansopon J, a al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995;92:2755-9.
26. 26 Chang KM, Rehermann B, McHutchison JG, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997;100:2376-85.
27. 27 Tsai SL, Chen YM, Chen MH, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998;115:954-65.
28. 28 Thursz MR, Kwiatkowski D, Allsopp CE, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-9.
29. 29 Thursz MR, Thomas HC, Greenwood BM, et al. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997;17:11-12.
30. 30 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
31. 31 Hohler T, Gerken G, Notghi A, et al. HLA-DRB1 * 1301 and * 1302 protect against chronic hepatitis B. J Hepatol 1997;26:503-7.
32. 32 Minton EJ, Smillie D, Neal KR, et al. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis 1998;178:39-44.
33. 33 Alric L, Fort M, Izopet J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997;113:1675-81.
34. 34 Hohler T, Gerken G, Notghi A, et al. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997;27:259-64.
35. 35 Zavaglia C, Martinetti M, Silini E, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepalol 1998;28:1-7.
36. 36 Moss PAH, Rosenberg WMC, Bell JI. The human T cell receptor in health and disease. Ann Rev Immunol 1992;10:71-96.
37. 37 Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-603.
38. 38 Jamieson BD, Ahmed R. T-cell tolerance: exposure to virus in utero does not cause a permanent deletion of specific T cells. Proc Natl Acad Sci USA 1988;85:2265-8.
39. 39 Bachmann MF, McKall Faienza K, Schmits R, et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 1997;7:549-57.
40. 40 Kundig TM, Shahinian A, Kawai K, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996;5:41-52.
41. 41 Moskophidis D, Lechner E, Pircher H, et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-61.
42. 42 Gallimore A, Glithero A, Godkin A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383-93.
43. 43 Marrack P, Hugo P, McCormack J, et al. Death and T cells. Immunol Rev 1993;133:119-29.
44. 44 Wodarz D, Klenerman P, Nowak MA. Dynamics of cytotoxic T-lymphocyte exhaustion. Proc R Soc Lond B Biol Sci 1998;265:191-203.
45. 45 Fazekas de St. Groth, Webster RG. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 1966;124:331-45.
46. 46 Fazekas De St. Groth, Webster RG. Disquisitions on original antigenic sin. II. Proof in lower creatures. J Exp Med 1966;124:347-61.
47. 47 Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998;394: 482-5.
48. 48 McMichael AJ. The original sin of killer T cells. Nature 1998;394:421-2.
49. 49 Siliciano RF, Lawton T, Knall C, et al. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 1988;54:561-75.
50. 50 Lanzavecchia A, Roosnek E, Gregory T, et al. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 1988; 334:530-2.
51. 51 Ferrari C, Penna A, Giuberti T, et al. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol 1987;139: 2050-8.
52. 52 Schirmbeck R, Melber K, Mertens T, et al. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J Virol 1994;68:1418-25.
53. 53 Schirmbeck R, Melber K, Kuhrober A, et al. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J Immunol 1994;152:1110-19.
54. 54 Swaminathan S, Hesselton R, Sullivan J, et al. Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. J Virol 1993;67: 7406-13.
55. 55 Ryon JJ, Hayward SD, MacMahon EM, et al. In situ detection of lytic Epstein-Barr virus infection: expression of the Notl early gene and viral interleukin-10 late gene in clinical specimens. J Infect Dis 1993;168:345-51.
56. 56 Colamonici OR, Domanski P, Sweitzer SM, et al. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 1995;270:15974-8.
57. 57 Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995;81:551-60.
58. 58 Spriggs MK, Hruby DE, Maliszewski CR, et al. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 1992;71:145-52.
59. 59 Smith GL, Chan YS. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol 1991;72:511-18.
60. 60 Upton C, Mossman K, McFadden G. Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Seiend 1992;258:1369-72.
61. 61 Horton TM, Ranheim TS, Aquino L, et al. Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol 1991;65:2629-39.
62. 62 Wold WS, Gooding LR. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991;184:1-8.
63. 63 Twu JS, Schloemer RH. Transcription of the human beta interferon gene is inhibited by hepatitis B virus. J Virol 1989;63:3065-71.
64. 64 Twu JS, Lee CH, Lin PM, et al. Hepatitis B virus suppresses expression of human beta-interferon. Proc Natl Acad Sci USA 1988;85:252-6.
65. 65 Foster GR, Ackrill AM, Goldin RD, et al. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Prof Natl Acad Sci USA 1991;88: 2888-92.
66. 66 Matsumoto M, Hsieh TY, Zhu N, et al. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997;71:1301-9.
67. 67 Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-14.
68. 68 Tsai SL, Liaw YF, Chen MH, et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997;25:449-58.
69. 69 Kaneko T, Moriyama T, Udaka K, et al. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur J Immunol 1997;27:1782-7.
70. 70 Hoffmann RM, Diepolder HM, Zachoval R, et al. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995;21: 632-8.
71. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997;71:6011-19.
72. 72 Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 1997;19:69-83.
73. 73 Wong DK, Dudley DD, Afdhal NH, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998;160:1479-88.
74. 74 Ballardini G, Groff P, Pontisso P, et al. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 1995;95:2067-75.
75. 75 Mochizuki K, Hayashi N, Katayama K, et al. B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology 1997;25:713-18.
76. 76 Ho MS, Lu CF, Kuo J, et al. A family cluster of an immune escape variant of hepatitis B virus infecting a mother and her two fully immunized children. Clin Diagn Lab Immunol 1995;2:760-2.
77. 77 Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of non-response to hepatitis B vaccine. N Engl J Med 1989;321:708.
78. 78 Gurunathan S, Irvine KR, Wu C-Y, et al. CD40 Ligand/Trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumour challenge. J Immunol 1998; 161:4563-71.